Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
2.150
+0.040 (1.90%)
Oct 11, 2024, 4:00 PM EDT - Market closed
Senti Biosciences Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Senti Biosciences.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for SNTI.
Recommendation Trends
Rating | Mar '23 | Apr '23 | May '23 | Jun '23 | Jul '23 | Aug '23 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 4 | 4 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Chardan Capital | Chardan Capital | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +2,690.70% | Aug 15, 2023 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $70 → $60 | Strong Buy | Maintains | $70 → $60 | +2,690.70% | May 11, 2023 |
Morgan Stanley | Morgan Stanley | Hold Maintains $30 → $20 | Hold | Maintains | $30 → $20 | +830.23% | Mar 24, 2023 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $80 → $70 | Strong Buy | Maintains | $80 → $70 | +3,155.81% | Mar 23, 2023 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $120 → $80 | Strong Buy | Maintains | $120 → $80 | +3,620.93% | Jan 30, 2023 |
Financial Forecast
Revenue This Year
9.08M
from 2.56M
Increased by 254.47%
Revenue Next Year
24.48M
from 9.08M
Increased by 169.66%
EPS This Year
-0.77
from -16.01
EPS Next Year
-0.23
from -0.77
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | 14.7M | 25.2M |
Avg | 9.1M | 24.5M |
Low | 3.7M | 23.5M |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | 474.0% | 177.6% |
Avg | 254.5% | 169.7% |
Low | 45.4% | 159.1% |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -0.54 | -0.24 |
Avg | -0.77 | -0.23 |
Low | -0.98 | -0.23 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.